$6.40
1.11% yesterday
Nasdaq, Jan 06, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG

MiMedx Group, Inc. Stock price

$6.40
-0.28 4.19% 1M
-0.08 1.23% 6M
-0.37 5.47% YTD
-2.51 28.17% 1Y
+3.19 99.38% 3Y
-2.94 31.48% 5Y
-2.50 28.09% 10Y
+6.30 6,300.00% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
+0.07 1.11%
ISIN
US6024961012
Symbol
MDXG
Industry

Key metrics

Basic
Market capitalization
$947.9m
Enterprise Value
$824.0m
Net debt
positive
Cash
$142.1m
Shares outstanding
148.1m
Valuation (TTM | estimate)
P/E
23.7 | 14.9
P/S
2.4 | 2.3
EV/Sales
2.1 | 2.0
EV/FCF
12.3
P/B
4.0
Financial Health
Equity Ratio
73.2%
Return on Equity
22.0%
ROCE
20.7%
ROIC
24.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$393.4m | $415.6m
EBITDA
$54.5m | $103.3m
EBIT
$54.0m | $68.1m
Net Income
$40.8m | $63.4m
Free Cash Flow
$66.8m
Growth (TTM | estimate)
Revenue
14.8% | 19.1%
EBITDA
-15.0% | 97.8%
EBIT
-14.8% | 34.5%
Net Income
-50.2% | 49.6%
Free Cash Flow
19.9%
Margin (TTM | estimate)
Gross
82.0%
EBITDA
13.9% | 24.9%
EBIT
13.7%
Net
10.4% | 15.3%
Free Cash Flow
17.0%
More
EPS
$0.3
FCF per Share
$0.5
Short interest
3.9%
Employees
837
Rev per Employee
$420.0k
Show more

Is MiMedx Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

MiMedx Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a MiMedx Group, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a MiMedx Group, Inc. forecast:

Buy
91%
Hold
9%

Financial data from MiMedx Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
393 393
15% 15%
100%
- Direct Costs 71 71
24% 24%
18%
323 323
13% 13%
82%
- Selling and Administrative Expenses 254 254
16% 16%
65%
- Research and Development Expense 14 14
59% 59%
4%
55 55
15% 15%
14%
- Depreciation and Amortization 0.50 0.50
34% 34%
0%
EBIT (Operating Income) EBIT 54 54
15% 15%
14%
Net Profit 41 41
50% 50%
10%

In millions USD.

Don't miss a Thing! We will send you all news about MiMedx Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MiMedx Group, Inc. Stock News

Neutral
GlobeNewsWire
16 days ago
MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.
Neutral
GlobeNewsWire
about 2 months ago
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)
Neutral
GlobeNewsWire
about 2 months ago
MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16 th Annual Alpha Select Conference | New York, NY Tuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New...
More MiMedx Group, Inc. News

Company Profile

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.

Head office United States
CEO Joe Capper
Employees 837
Founded 1985
Website mimedx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today